EPISODE · May 13, 2026 · 1 MIN
Papzimias: Revolutionizing RRP Treatment
from The Daily News Now! Business
Papzimias, the first approved treatment for adults with recurrent respiratory papillomatosis, has made a strong start with $21.6 million in net revenue in its first full quarter. With over 90% payer coverage and positive feedback from doctors, its gaining traction as the new standard. The company expects to reach breakeven by the end of 2026, with redosing trials and a pediatric study underway. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/683388bd8fc6f161
NOW PLAYING
Papzimias: Revolutionizing RRP Treatment
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m